Micafungin injection for the treatment of invasive candidiasis in pediatric patients under 4 months of age

Nahed Abdel-Haq, Stephanie M. Smith, Basim I. Asmar

Research output: Contribution to journalArticlepeer-review


Introduction: Neonates and young infants with invasive candidiasis are particularly at increased risk of dissemination including hematogenous Candida meningoencephalitis. The echinocandins including micafungin have emerged as a preferred agent in most cases of candidemia and invasive candidiasis but data in pediatric patients under 4 months of age are limited. Areas covered: In this report, we review the micafungin use in infants younger than 4 months of age. Animal studies as well as clinical data that support its use in neonatal candidiasis are reviewed. In addition, the status of FDA approval and the rationale of micafungin dosing recommendations in infants <4 months are discussed. Expert Opinion: A dose of 4 mg/kg was approved for treatment of candidemia, Candida peritonitis and abscesses excluding meningoencephalitis or ocular involvement in patients younger than 4 months of age. However, because of the risk of central nervous system dissemination as well as the difficulty in establishing this diagnosis, this dose is inadequate to treat ill infants with candidemia. More studies are needed to establish the safety and efficacy of micafungin daily dose of at least 10 mg/kg in infants younger than 4 months of age when hematogenous Candida meningoencephalitis or ocular involvement cannot be excluded.

Original languageEnglish
Pages (from-to)493-505
Number of pages13
JournalExpert Review of Anti-Infective Therapy
Issue number4
StatePublished - 2022


  • Candidiasis
  • infants
  • meningitis
  • micafungin
  • neonates


Dive into the research topics of 'Micafungin injection for the treatment of invasive candidiasis in pediatric patients under 4 months of age'. Together they form a unique fingerprint.

Cite this